Display options
Cite
Bornaun H, Öztarhan K, Erener-Ercan T, et al. Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment. Case Rep Pediatr. 2016;2016:8712962doi: 10.1155/2016/8712962.
Bornaun, H., Öztarhan, K., Erener-Ercan, T., Dedeoğlu, R., Tugcu, D., Aydoğmuş, �. �., Cetinkaya, M., & Kavuncuoglu, S. (2016). Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment. Case reports in pediatrics, 20168712962. https://doi.org/10.1155/2016/8712962
Bornaun, Helen, et al. "Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment." Case reports in pediatrics vol. 2016 (2016): 8712962. doi: https://doi.org/10.1155/2016/8712962
Bornaun H, Öztarhan K, Erener-Ercan T, Dedeoğlu R, Tugcu D, Aydoğmuş Ç, Cetinkaya M, Kavuncuoglu S. Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment. Case Rep Pediatr. 2016;2016:8712962. doi: 10.1155/2016/8712962. Epub 2016 Jun 27. PMID: 27429821; PMCID: PMC4939353.
Copy Download .nbib Format: NLM
Share it on

Case Rep Pediatr. 2016;2016:8712962. doi: 10.1155/2016/8712962. Epub 2016 Jun 27.

Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment.

Case reports in pediatrics

Helen Bornaun, Kazım Öztarhan, Tugba Erener-Ercan, Reyhan Dedeoğlu, Deniz Tugcu, Çiğdem Aydoğmuş, Merih Cetinkaya, Sultan Kavuncuoglu

Affiliations

  1. Department of Pediatric Cardiology, Kanuni Suleyman Teaching and Research Hospital, 34303 Istanbul, Turkey.
  2. Department of Neonatology, Kanuni Suleyman Teaching and Research Hospital, 34303 Istanbul, Turkey.
  3. Department of Pediatric Cardiology, Cerrahpasa Medical Faculty, Istanbul University, 34098 Istanbul, Turkey.
  4. Department of Pediatric Hematology-Oncology, Kanuni Suleyman Teaching and Research Hospital, 34303 Istanbul, Turkey.

PMID: 27429821 PMCID: PMC4939353 DOI: 10.1155/2016/8712962

Abstract

Cardiac rhabdomyoma often shows spontaneous regression and usually requires only close follow-up. However, patients with symptomatic inoperable rhabdomyomas may be candidates for everolimus treatment. Our patient had multiple inoperable cardiac rhabdomyomas causing serious left ventricle outflow-tract obstruction that showed a dramatic reduction in the size after everolimus therapy, a mammalian target of rapamycin (mTOR) inhibitor. After discontinuation of therapy, an increase in the diameter of masses occurred and everolimus was restarted. After 6 months of treatment, rhabdomyomas decreased in size and therapy was stopped. In conclusion, everolimus could be a possible novel therapy for neonates with clinically significant rhabdomyomas.

References

  1. Pediatr Surg Int. 2007 Aug;23(8):811-4 - PubMed
  2. Pediatrics. 2011 May;127(5):e1335-7 - PubMed
  3. Turk J Pediatr. 2013 Jan-Feb;55(1):69-73 - PubMed
  4. Fetal Pediatr Pathol. 2004 Jul-Aug;23(4):241-9 - PubMed
  5. Pediatrics. 2012 Jul;130(1):e243-7 - PubMed
  6. Rev Port Cardiol. 2009 Mar;28(3):279-88 - PubMed
  7. Cardiovasc Pathol. 2007 Jan-Feb;16(1):22-8 - PubMed
  8. Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92 - PubMed
  9. J Pediatr. 2003 Nov;143(5):620-4 - PubMed

Publication Types